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Abstract
Acute kidney injury (AKI) in hospitalized patients is
independently associated with increased morbidity
and mortality in pediatric and adult populations.
Continued reliance on serum creatinine and urine
output to diagnose AKI has resulted in our inability to
provide successful therapeutic and supportive
interventions to prevent and mitigate AKI and its
effects. Research efforts over the last decade have
focused on the discovery and validation of novel
urinary biomarkers to detect AKI prior to a change in
kidney function and to aid in the differential diagnosis
of AKI. The aim of this article is to review the AKI
biomarker literature with a focus on the context in
which they should serve to add to the clinical context
facing physicians caring for patients with, or at-risk for,
AKI. The optimal and appropriate utilization of AKI
biomarkers will only be realized by understanding
their characteristics and placing reasonable
expectations on their performance in the clinical
arena.
Background
A c u t ek i d n e yi n j u r y( A K I )i sd e f i n e da sa na b r u p t
decrease in kidney function, which in its most severe
form, acute renal failure, is manifested by changes in
blood chemistry and decreased urine output [1]. AKI
rates among hospitalized adults and children have been
rising over the past two decades. Discharge coding data
from a 5% sample of United States Medicare benefici-
aries (n = 5.4 million) demonstrated an 11% annual
increase in AKI prevalence in hospitalized adults
between 1992 and 2001 (the prevalence increased from
14.2 to 34.6 AKI cases per 100 patient discharges) [2].
AKI rates likewise increased 20-fold, from 0.5 to 9.9
cases per 1,000 hospitalized children, between 1982 to
2004 [3].
T h eA K Il a n d s c a p eh a su n d e r g o n eas e i s m i cs h i f ti n
the last ten years. Prior to 2004, the definition of AKI
was not standardized, with more than 30 different defi-
nitions used in the published literature [4]. Rigorous
assessment of cross-sectional and longitudinal epide-
miology of any condition requires a standard definition.
The reassessment of AKI epidemiology with a focus on
organ crosstalk [5-7], standardization of the AKI defini-
tion [4,8,9], collaborative multi-center continuous renal
replacement therapy (CRRT) research [10-12], and
recognition of chronic kidney disease (CKD) develop-
ment in AKI survivors [13], all point to a renewed
understanding that AKI is far from a benign syndrome.
In fact, the realization that patients are dying ‘from’ and
not just ‘with’ AKI [14], and that pre-renal azotemia
may not be a benign disease state [15], have created the
impetus to prevent or mitigate the effects of AKI. How-
ever, clinicians caring for patients with AKI have been
hindered by the reliance on serum creatinine or
decreased urine output, both kidney function markers,
to make the AKI diagnosis. In the setting of acute tubu-
lar necrosis (ATN), these functional changes only mani-
fest after significant kidney damage has taken place.
Even more vexing is the fact that similar serum creati-
nine changes can occur without kidney damage, for
example in the context of dehydration, nephrotic syn-
drome or hepatorenal syndrome. In light of the inde-
pendent association between AKI and mortality rates of
up to 60% in critically ill patients and our current ability
to only provide supportive care for patients with AKI,
the need for more precise and earlier diagnostic tools is
profound.
Optimal therapeutic interventions require expeditious
diagnosis for any disease state. The advancements in
cardiac and oncological treatments over the past dec-
ades have in large part been enabled by the discovery,
validation and implementation of new biomarkers of
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ques as well as specific markers of cardiac myoblast
injury or the genetic subtypes of specific cancers. The
myocardial ischemia diagnostic paradigm has moved
from electrocardiographic changes, to creatine phoshop-
kinase (CPK) measurement, to specific CPK subtype
enzymatic changes, to the troponins and now to brain
natriuretic peptide (BNP). As a result, the sensitivity and
specificity to detect earlier myocardial ischemia has pro-
gressively increased, directing earlier intervention that
has transformed the field and substantially decreased
patient mortality [16,17].
Extensive research efforts over this past decade have
been directed at the discovery and validation of novel
AKI biomarkers to detect injury prior to changes in kid-
ney function and potentially to aid in the differential
diagnosis of AKI. The quest for such biomarkers has
often been referred to as the ‘search for the renal tropo-
nin I’. The analogy to troponin I and its acceptance for
prompt evaluation and therapeutic intervention in at-
risk patients with the clinical presentation of chest pain
is an informative and potentially applicable model to the
AKI field [18]. Nephrologists and intensivists must
define a ‘renal angina syndrome’ to initiate optimal
assessment with AKI biomarkers to realize their full
potential to improve patient care and outcomes.
The purpose of this article is to review the relevant
AKI biomarker literature in terms of a contextual frame-
work to aid in the clinical diagnosis of AKI prior to
changes in kidney function. In addition, the empiric pro-
drome of ‘renal angina’ will be discussed to highlight the
need to direct AKI biomarker assessment only where it
will optimize clinical care by detecting AKI early, refin-
ing AKI differential diagnosis and/or providing informa-
tion regarding AKI severity. Finally, very recent data
demonstrate that AKI biomarker ‘positive’ but serum
creatinine ‘negative’ AKI has an equally poor prognosis
with classical functional AKI [19], suggesting that we
may be on the verge of a new, more targeted definition
of AKI based on novel biomarkers.
Serum creatinine - the gold standard is a late marker of
kidney injury
AKI detection and differential diagnosis has been mired
in reliance on the same functional marker, serum creati-
nine, used to diagnose chronic kidney disease. Unfortu-
nately, serum creatinine concentrations do not change
until significant injury and loss of nephron function has
occurred. Chertow and colleagues demonstrated that a
serum creatinine rise of ≥ 0.3 mg/dl in hospitalized
adults was independently associated with a four-fold
increased risk of mortality, even when controlling for
diabetes, advanced heart failure, ethnicity and age [20].
Multiple studies using the RIFLE (Risk, Injury, Failure,
End-Stage Renal Disease) or Acute Kidney Injury Net-
work criteria in more than 550,000 patients demon-
strated that a 50% rise in serum creatinine is associated
with adult patient mortality [21]. Similar data have been
published in children with acute decompensated heart
failure, showing that a ≥ 0.3 mg/dl rise in serum creati-
nine is independently associated with death or the need
for mechanical ventricular assistance [22]. Since such
small rises in serum creatinine already reflect indepen-
dent morbidity and mortality risk, the need for earlier
true markers of AKI has become critical.
AKI biomarkers - the road to validation
An ideal AKI biomarker should be accurate, reliable,
easy to measure with a standard assay, non-invasive,
reproducible and sensitive and specific with defined cut-
off values [23]. Urine represents an ideal body fluid for
AKI biomarker assessment as it can be obtained non-
invasively and repeatedly from a spontaneously voided
sample or from an indwelling bladder catheter. The
road to AKI biomarker validation spans discovery in
pre-clinical studies from bodily fluids, assay develop-
ment, retrospective study in completed trials and then
prospective screening in ongoing trials [23]. These
phases must be completed before a biomarker can be
used broadly in clinical practice. Four AKI biomarkers,
neutrophil gelatinase-associated lipocalin (NGAL), inter-
leukin 18 (IL-18), Kidney Injury Molecule -1 (KIM-1)
and Liver Fatty Acid Binding Protein (L-FABP) have
been tested to various degrees in ongoing clinical trials
[24].
Putting AKI biomarkers to the test: the paradigm of AKI
after cardiopulmonary bypass
Most early AKI biomarker validation studies have
occurred in patients after cardiopulmonary bypass
[25-27] or renal transplantation [28]. The reasons for
selecting these populations are apparent: the timing of
kidney injury is known, biomarkers can be assessed
repeatedly after the event, and the AKI event rates after
these procedures are well documented. In addition,
many early trials assessed AKI biomarkers in children,
since they do not have many of the co-morbidities
(chronic kidney disease, diabetes, chronic inflammatory
diseases) that could potentially confound AKI studies.
As a result, one could reasonably argue if an AKI bio-
marker does not demonstrate adequate sensitivity and/
or specificity for predicting AKI development, severity
or duration in a child after cardiopulmonary bypass
(CPB), then it would be unlikely to perform well in the
adult population.
The initial prospective human study of urinary NGAL
occurred in the pediatric CPB setting [25]. Seventy-one
children were enrolled and AKI was defined as a serum
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detected and rose 100-fold 2 hours after CPB was
initiated in the 21 patients who ultimately developed
AKI, whereas NGAL did not rise in the urine of patients
who did not develop AKI. Most importantly, serum
creatinine concentrations did not increase in AKI
patients until 36 to 48 hours after the NGAL increase,
which provides a heretofore unavailable potential thera-
peutic window to intervene and prevent or mitigate
AKI.
Subsequently, multiple studies have confirmed the
predictive ability of NGAL in the pediatric CPB setting
[29-31]. In addition to NGAL, IL-18, KIM-1 [32] and L-
FABP [27] have been studied in the post-CPB setting.
Very recent data from the large US National Institutes
of Health (NIH)-funded multi-center Translational
Research Investigating Biomarker Endpoints in Acute
Kidney Injury (TRIBE-AKI) consortium has also demon-
strated both urinary NGAL and IL-18 [26] in children
[33] and adults [34] after CPB. In both populations,
NGAL and IL-18 demonstrated moderate predictive
ability for AKI with a significant improvement above
clinical risk factors alone. The TRIBE-AKI experience
has set the standard for AKI biomarker assessment and
statistical analysis. Additionally, the consortium plans to
follow survivors longitudinally to assess for development
of chronic kidney disease. Finally, one very recent study
has evaluated the complete ‘panel’ of these four AKI
biomarkers in the pediatric CPB setting [35]. In this
study, we demonstrated a temporal pattern of biomarker
elevation, with NGAL elevated at 2 hours, IL-18 and L-
FABP elevated at 6 hours and KIM-1 elevated at 12
hours in patients who developed AKI after CPB initia-
tion. As with the TRIBE-AKI cohort, urinary biomarkers
improved the predictive ability for AKI compared with
clinical risk factors alone. This discovery of a temporal
pattern argues for the combination of biomarkers in a
panel to allow for more precise assessment of the time
course of AKI, which would theoretically inform clinical
trials in terms of the timing of intervention.
Validation in other populations
Subsequent to the initial promising results observed for
novel biomarker prediction of AKI development and
severity after CPB, biomarkers (especially NGAL [36])
have been assessed in multiple other clinical AKI set-
tings including contrast induced nephropathy [37,38],
hemolytic uremic syndrome (HUS) [39], lupus nephritis
[40], and renal [28,41,42] and orthotopic hepatic trans-
plantation [43]. Once again, AKI biomarkers should be
validated in these disease states as they contain either a
known timing or mechanism of injury (nephrotoxins or
surgery), or they represent a primary acute kidney dis-
ease (lupus nephritis, HUS, kidney transplantation).
In addition, other non-surgical or non-kidney specific
disease states such as acute decompensated heart fail-
ure-associated cardiorenal syndrome may provide an
excellent arena to study novel AKI biomarkers [17]. The
use of biomarkers in other systemic illnesses with
unknown timing of insult, such as septic shock or criti-
cal illness, represents a major challenge for biomarkers
to predict AKI development and/or severity. Our initial
work in critically ill children receiving invasive mechani-
cal ventilation and at least one vasoactive medication
demonstrated that NGAL [44] and IL-18 [45] could pre-
d i c tu l t i m a t eA K Is e v e r i t yb yt h ep R I F L Es c o r ea n d
duration of AKI. In addition, NGAL rose two days prior
to serum creatinine in all patients who developed AKI,
and IL-18 rose 2 days prior to serum creatinine in non-
septic patients who developed AKI. Recent biomarker
data from adults measured in the ICU demonstrated
reasonable performance of NGAL, IL-18 and Cystatin C
to predict AKI when stratified by baseline estimated glo-
merular filtration rate (eG F R )a n da td i f f e r e n tt i m e
points within the first two days of ICU stay [46].
The next phase for AKI biomarkers
All of the AKI biomarker work performed to date has
focused on discovery and validation of AKI biomarkers
in a post-hoc manner; samples for biomarkers have
been obtained and stored for later assessment of their
ability to predict AKI development or severity. The next
challenge for AKI biomarkers is to test their ability to
direct therapeutic intervention or other clinical manage-
ment. Yet, the heterogeneity of patient populations and
varying precision of AKI biomarkers noted above pre-
sents a significant risk for inappropriate use of AKI bio-
markers to decrease their utility. Recent statistical
methods such as the net reclassification index must be
used to ensure that biomarker concentration thresholds
add predictive value to the clinical model alone in pre-
dicting the AKI spectrum. A recent concept of a pro-
dome of ‘renal angina’ has been proposed to direct
biomarker assessment only in patients who fulfill a com-
bination of illness severity/risk and small changes in kid-
ney function (creatinine changes or fluid overload)
[18,47]. The renal angina concept is based on the high
negative predictive value of the construct; patients who
do not fulfill renal angina should not have biomarker
assessment as their risk of developing AKI is extremely
low. However, renal angina presence only increases AKI
development risk and biomarkers should add value to
predict the AKI spectrum and help guide management.
Conclusions
As discussed above, AKI biomarkers have been validated
retrospectively in multiple patient populations. The
c h a l l e n g ef o rt h ef u t u r ei st ou s et h e s ed a t at od e s i g n
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to test the value of AKI biomarkers in improving the
outcome for patients with, or at-risk for, AKI. Only after
AKI biomarkers have been validated prospectively in the
appropriate populations will widespread and rational
adoption be possible.
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